Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
78 hedge funds and large institutions have $74.6M invested in Synergy Pharmaceuticals, Inc Common Stock in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 30 reducing their positions, and 13 closing their positions.
48% more call options, than puts
Call options by funds: $319K | Put options by funds: $216K
9% less funds holding
Funds holding: 86 → 78 (-8)
23% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 30
37% less capital invested
Capital invested by funds: $118M → $74.6M (-$43.4M)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$653K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$539K |
| 3 |
Goldman Sachs
New York
|
+$404K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$402K |
| 5 |
Bank of New York Mellon
New York
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$3.65M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.85M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$997K |
| 4 |
Millennium Management
New York
|
-$885K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$881K |
SGYP Hedge Fund Activity: Q3 2014 in Review
78 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2014, worth a combined $74.6M — down 37% from $118M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SGYP and 6 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 23 added.
The largest buyer was Cowen Inc, opening a new position worth an estimated $653K. The largest seller was State Street, cutting an estimated $3.65M.
- 78 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2014, down from 86 in Q2 2014.
- Funds reported $74.6M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2014, down 37% quarter-over-quarter.
- 6 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2014 and 13 closed out, a net change of -7 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2014 was Cowen Inc, an estimated $653K added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2014 was State Street, an estimated $3.65M sold.
Based on aggregated 13F filings for Q3 2014.